Theory Paper IDrNB Cardiology – Theory Notes
PDA (PATENT DUCTUS ARTERIOSUS) DEVICE CLOSURE: CURRENT STATUS
IANATOMICAL CLASSIFICATION (KRICHENKO CLASSIFICATION, 1989)
- Anatomical Basis: The Patent Ductus Arteriosus (PDA) connects the roof of the main/proximal left pulmonary artery to the anterior wall of the proximal descending thoracic aorta just distal to the left subclavian artery.
- Krichenko Angiographic Types (Lateral Aortogram): Dictates device selection:
- Type A (Conical — ~65%): Well-defined aortic ampulla tapering to a discrete constriction at the pulmonary arterial insertion.
- Type B (Window — ~18%): Very short, wide, window-like ductus narrowed at the aortic insertion.
- Type C (Tubular — ~8%): Tubular configuration throughout its length without any focal constriction.
- Type D (Complex — ~4%): Ductus with multiple constrictions and intervening aneurysmal segments.
- Type E (Elongated — ~5%): Bizarre, elongated conical ductus with the constriction remote from the anterior tracheal border (characteristic of premature infants, often termed Type F “Fetal/Hockey-stick” ductus in dedicated premature classifications).
IIINDICATIONS AND CONTRAINDICATIONS FOR CLOSURE (ESC 2020 ACHD / ACC-AHA 2018)
- Class I Indications (Recommended):
- Left Heart Volume Overload: Evidence of Left Atrial (LA) and/or Left Ventricular (LV) enlargement due to significant left-to-right shunting (Qp:Qs of 1.5:1 or greater) with PVR less than 3 Wood Units, regardless of symptoms.
- Symptomatic Patients or Prior Endarteritis: Congestive heart failure, failure to thrive in infants, exercise intolerance, or a prior episode of infective endarteritis.
- Modality of Choice: Transcatheter device closure is the Class I treatment of choice in adults and children when anatomically suitable.
- Class IIa Indications (Should Be Considered):
- Borderline PAH (PVR 3 to less than 5 Wood Units): Closure should be considered when a significant net left-to-right shunt (Qp:Qs greater than 1.5) persists.
- Small Audible PDA without LV Overload: Closure is reasonable in a small PDA with an audible continuous murmur and normal LV dimensions to eliminate the lifetime risk of infective endarteritis.
- Class IIb Indications (May Be Considered):
- Severe PAH (PVR 5 Wood Units or Greater): May be considered in expert centers only if Qp:Qs remains greater than 1.5 and trial balloon/device occlusion (or targeted PAH medical therapy) confirms a significant drop in PA pressure without a fall in systemic aortic pressure.
- Class III (Contraindicated / Harm):
- Eisenmenger PDA: Persistent PVR of 5 Wood Units or greater with bidirectional or right-to-left shunting (differential cyanosis and clubbing of the lower extremities/toes, or resting/exercise lower-limb desaturation).
- Silent PDA: Tiny PDA detected incidentally on color Doppler echocardiography without an audible murmur.
IIIPROCEDURAL TECHNIQUES AND DEVICE SELECTION
- Vascular Access and Crossing: Standard femoral venous (for antegrade delivery across the right heart and PA into the descending aorta) and femoral arterial access (for lateral descending aortography to measure minimal ductal diameter, ampulla size, and length). In premature and small infants, a venous-only TTE-guided approach is used to avoid femoral arterial injury.
- Device Selection by Ductal Morphology:
- Amplatzer Duct Occluder I (ADO I) / Cocoon / Cera Duct Occluder: Single aortic retention disc with a tapered cylindrical body (sized 2 mm larger than the minimal pulmonary ductal diameter); the workhorse for Type A conical PDAs greater than 2 mm.
- Amplatzer Duct Occluder II (ADO II): Flexible nitinol mesh with two symmetrical retention discs and an articulating central waist deliverable through a 4F or 5F catheter from either the venous or arterial side; ideal for small-to-moderate (<4 to 5.5 mm) Type A, Type C tubular, or Type E elongated PDAs.
- Amplatzer Vascular Plug II (AVP II) or Muscular VSD Occluder: Multi-lobed or high-radial-strength double-disc devices used for large tubular Type C PDAs or hypertensive adult PDAs.
- Detachable Coils (Flipper / Gianturco): Used for very small PDAs (minimal diameter less than 1.5 to 2.0 mm).
| PDA Morphology / Clinical Group | Preferred Transcatheter Device | Sizing & Technical Pearl |
|---|---|---|
| Type A Conical PDA (>2.0 mm) | Amplatzer Duct Occluder I (ADO I) | Select pulmonary end >=2 mm larger than narrowest ductal diameter; antegrade venous delivery |
| Small / Tubular / Elongated PDA (<4–5 mm) | ADO II or Amplatzer Vascular Plug II (AVP II) | Symmetrical dual discs; low profile via 4F/5F sheath (venous or retrograde arterial) |
| Very Small PDA (<1.5–2.0 mm) | Detachable Coils or ADO II | Simple retrograde or antegrade delivery; avoid residual high-velocity jet (hemolysis) |
| Premature / ELBW Infant (>=700 grams) | Amplatzer Piccolo Occluder (FDA approved 2019) | Implanted completely intraductally via 4F femoral venous-only TTE-guided approach (avoids LPA/aortic obstruction) |
| Large Hypertensive Adult PDA | Muscular VSD Occluder | Dual retention discs prevent systemic-pressure embolization into PA |
IVTHE PREMATURE INFANT PARADIGM SHIFT (AMPLATZER PICCOLO OCCLUDER)
- The Clinical Problem: Hemodynamically significant PDA in extremely low birth weight (ELBW) premature infants causes pulmonary hemorrhage, prolonged mechanical ventilation, bronchopulmonary dysplasia, and necrotizing enterocolitis; while cyclooxygenase inhibitors (indomethacin, ibuprofen) or paracetamol often fail, surgical thoracotomy ligation carries risks of post-ligation low cardiac output syndrome, left recurrent laryngeal nerve palsy (vocal cord paralysis), phrenic nerve injury, chylothorax, and scoliosis.
- The Amplatzer Piccolo Occluder Breakthrough (Pivotal Trial, JACC Cardiovasc Interv 2020): A low-profile, symmetrical nitinol device approved for premature infants weighing as little as 700 grams (and age >=3 days). Delivered via a 4F femoral venous-only approach under bedside Transthoracic Echocardiography (TTE) and fluoroscopic guidance (zero arterial access and minimal contrast), the entire device is packed completely inside the fetal ductus (intraductal placement) so that neither disc protrudes into the tiny neonatal descending aorta or left pulmonary artery—achieving 95.5 to 99 percent implant success and rapid ventilator weaning.
VCOMPLICATIONS AND OUTCOMES
- Device Embolization (less than 1 percent): Embolization into the Pulmonary Artery (from undersizing) or Descending Aorta; retrieved percutaneously with a gooseneck snare or surgically.
- Iatrogenic Aortic Coarctation or Left Pulmonary Artery (LPA) Stenosis: Caused by protrusion of the aortic retention disc into the aortic isthmus or the pulmonary end into the origin of the LPA (especially in infants weighing less than 6 kg). Mandatory pre-release TTE and pullback pressure assessment must confirm no LPA or descending aortic flow acceleration (Doppler velocity must remain less than 2.0 m/s without a diastolic tail).
- Mechanical Intravascular Hemolysis (0.5 percent): High-velocity residual shunt jet shearing red blood cells against the nitinol/polyester mesh, presenting with hemoglobinuria within 24 hours; managed with hydration, transcatheter coil/plug closure of the residual leak, or device retrieval if refractory.
- Long-Term Outcomes: Complete closure rates exceed 98 to 99 percent at 6 to 12 months, establishing transcatheter occlusion as the definitive gold standard over surgery across virtually all weight and age groups (except giant non-constricting window-type ducts exceeding available device sizes).
Key references
- Krichenko A, Benson LN, Burrows P, Möes CA, McLaughlin P, Freedom RM: Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion, American Journal of Cardiology, 1989.
- Sathanandam SK, Gutfinger D, O’Brien L, et al.: Amplatzer Piccolo Occluder clinical trial for percutaneous closure of the patent ductus arteriosus in patients >=700 grams, JACC: Cardiovascular Interventions, 2020.
- Baumgartner H, De Backer J, Babu-Narayan SV, et al.: 2020 ESC Guidelines for the management of adult congenital heart disease, European Heart Journal, 2020.
meritmedscript.comDr. Sidhartha Mullapudi
